Baldwin Wealth Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Baldwin Wealth Partners’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50	Closed	-$3.49K	–	781
2024 Q3	$3.49K	Hold	50	–	–	﹤0.01%	905
2024 Q2	$3.24K	Hold	50	–	–	﹤0.01%	623
2024 Q1	$3.24K	Hold	50	–	–	﹤0.01%	621
2023 Q4	$3.29K	Hold	50	–	–	﹤0.01%	646
2023 Q3	$2.85K	Hold	50	–	–	﹤0.01%	668
2023 Q2	$3.06K	Hold	50	–	–	﹤0.01%	679
2023 Q1	$3.14K	Hold	50	–	–	﹤0.01%	707
2022 Q4	$3.17K	Buy	+50	New	+$3.17K	﹤0.01%	696
2016 Q1	–	Sell	-35,924	Closed	-$1.81M	–	504
2015 Q4	$1.81M	Sell	35,924 -8,209	-19%	-$406K	0.3%	80
2015 Q3	$2.02M	Buy	44,133 +473	+1%	+$26.4K	0.34%	62
2015 Q2	$2.55M	Buy	43,660 +430	+1%	+$24.6K	0.38%	64
2015 Q1	$2.38M	Sell	43,230 -155	-0.4%	-$8.38K	0.35%	68
2014 Q4	$2.18M	Buy	43,385 +10,381	+31%	+$508K	0.31%	72
2014 Q3	$1.52M	Buy	+33,004	New	+$1.49M	0.22%	92

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Baldwin Wealth Partners's PBE Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2024, closing a stake of 50 shares — an estimated $3.49K sold.

Baldwin Wealth Partners first reported a position in PBE in Q3 2014 and held it in 14 quarters. The position peaked at $2.55M in Q2 2015. 96 funds tracked by Wall St. Rank hold PBE as of Q4 2024.

Baldwin Wealth Partners reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 50 Invesco Biotechnology & Genome ETF shares in Q4 2024, an estimated $3.49K.
Baldwin Wealth Partners first reported a position in Invesco Biotechnology & Genome ETF in Q3 2014 and held it in 14 quarters.
Baldwin Wealth Partners's Invesco Biotechnology & Genome ETF position peaked at $2.55M in Q2 2015.
96 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.